ES2324909T3 - Preparado con principio activo en forma de pelicula con mejora de la estabilidad quimica y procedimiento para su fabricacion. - Google Patents
Preparado con principio activo en forma de pelicula con mejora de la estabilidad quimica y procedimiento para su fabricacion. Download PDFInfo
- Publication number
- ES2324909T3 ES2324909T3 ES03735367T ES03735367T ES2324909T3 ES 2324909 T3 ES2324909 T3 ES 2324909T3 ES 03735367 T ES03735367 T ES 03735367T ES 03735367 T ES03735367 T ES 03735367T ES 2324909 T3 ES2324909 T3 ES 2324909T3
- Authority
- ES
- Spain
- Prior art keywords
- active
- preparation
- formulation
- prepared according
- peroxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000013543 active substance Substances 0.000 claims description 48
- 150000002978 peroxides Chemical class 0.000 claims description 48
- 238000002360 preparation method Methods 0.000 claims description 34
- 239000000203 mixture Substances 0.000 claims description 27
- 239000000126 substance Substances 0.000 claims description 27
- 239000004615 ingredient Substances 0.000 claims description 24
- 238000009472 formulation Methods 0.000 claims description 22
- 229920000642 polymer Polymers 0.000 claims description 22
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 18
- 239000001301 oxygen Substances 0.000 claims description 18
- 229910052760 oxygen Inorganic materials 0.000 claims description 18
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 13
- 239000011159 matrix material Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- -1 propylcellulose Polymers 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 239000003963 antioxidant agent Substances 0.000 claims description 10
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 9
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 235000010265 sodium sulphite Nutrition 0.000 claims description 7
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 6
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 6
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 230000007423 decrease Effects 0.000 claims description 5
- 239000006185 dispersion Substances 0.000 claims description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 5
- 210000000214 mouth Anatomy 0.000 claims description 5
- 230000003232 mucoadhesive effect Effects 0.000 claims description 5
- 238000007254 oxidation reaction Methods 0.000 claims description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 235000010980 cellulose Nutrition 0.000 claims description 4
- 229920003086 cellulose ether Polymers 0.000 claims description 4
- 238000000354 decomposition reaction Methods 0.000 claims description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 4
- 230000003647 oxidation Effects 0.000 claims description 4
- 239000001814 pectin Substances 0.000 claims description 4
- 229920001277 pectin Polymers 0.000 claims description 4
- 235000010987 pectin Nutrition 0.000 claims description 4
- 230000035515 penetration Effects 0.000 claims description 4
- 229920000058 polyacrylate Polymers 0.000 claims description 4
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 4
- 239000011118 polyvinyl acetate Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 4
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 4
- 235000019345 sodium thiosulphate Nutrition 0.000 claims description 4
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 claims description 4
- KUNNUNBSGQSGDY-UHFFFAOYSA-N 2-butyl-6-methylphenol Chemical compound CCCCC1=CC=CC(C)=C1O KUNNUNBSGQSGDY-UHFFFAOYSA-N 0.000 claims description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- 239000012736 aqueous medium Substances 0.000 claims description 3
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 235000015110 jellies Nutrition 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- 235000010981 methylcellulose Nutrition 0.000 claims description 3
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000004014 plasticizer Substances 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 229940001584 sodium metabisulfite Drugs 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 229940035024 thioglycerol Drugs 0.000 claims description 3
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 238000005266 casting Methods 0.000 claims description 2
- 229920002301 cellulose acetate Polymers 0.000 claims description 2
- 229910001882 dioxygen Inorganic materials 0.000 claims description 2
- 239000000975 dye Substances 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 235000003599 food sweetener Nutrition 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 239000008274 jelly Substances 0.000 claims description 2
- 229920001206 natural gum Polymers 0.000 claims description 2
- 239000000049 pigment Substances 0.000 claims description 2
- 239000004584 polyacrylic acid Substances 0.000 claims description 2
- 229920000193 polymethacrylate Polymers 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 229920002635 polyurethane Polymers 0.000 claims description 2
- 239000004814 polyurethane Substances 0.000 claims description 2
- 239000000758 substrate Substances 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 claims 1
- 238000001125 extrusion Methods 0.000 claims 1
- 238000007761 roller coating Methods 0.000 claims 1
- 238000005507 spraying Methods 0.000 claims 1
- 239000000080 wetting agent Substances 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 9
- 235000006708 antioxidants Nutrition 0.000 description 8
- 235000012431 wafers Nutrition 0.000 description 7
- 238000006731 degradation reaction Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 150000001298 alcohols Chemical class 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 4
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 4
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 4
- 229940041616 menthol Drugs 0.000 description 4
- 229960002715 nicotine Drugs 0.000 description 4
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 2
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 125000000746 allylic group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000001491 aromatic compounds Chemical class 0.000 description 2
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 2
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 description 2
- XIRNKXNNONJFQO-UHFFFAOYSA-N ethyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC XIRNKXNNONJFQO-UHFFFAOYSA-N 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- UQDUPQYQJKYHQI-UHFFFAOYSA-N methyl laurate Chemical compound CCCCCCCCCCCC(=O)OC UQDUPQYQJKYHQI-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- BEKZXQKGTDVSKX-UHFFFAOYSA-N propyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCC BEKZXQKGTDVSKX-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical group 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- LPMBTLLQQJBUOO-KTKRTIGZSA-N (z)-n,n-bis(2-hydroxyethyl)octadec-9-enamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)N(CCO)CCO LPMBTLLQQJBUOO-KTKRTIGZSA-N 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- FDVCQFAKOKLXGE-UHFFFAOYSA-N 216978-79-9 Chemical compound C1CC(C)(C)C2=CC(C=O)=CC3=C2N1CCC3(C)C FDVCQFAKOKLXGE-UHFFFAOYSA-N 0.000 description 1
- VTDOEFXTVHCAAM-UHFFFAOYSA-N 4-methylpent-3-ene-1,2,3-triol Chemical compound CC(C)=C(O)C(O)CO VTDOEFXTVHCAAM-UHFFFAOYSA-N 0.000 description 1
- UZNLHJCCGYKCIL-UHFFFAOYSA-N 6-ethoxy-6-oxohexanoic acid Chemical compound CCOC(=O)CCCCC(O)=O UZNLHJCCGYKCIL-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- AOMUHOFOVNGZAN-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)dodecanamide Chemical compound CCCCCCCCCCCC(=O)N(CCO)CCO AOMUHOFOVNGZAN-UHFFFAOYSA-N 0.000 description 1
- MMOXZBCLCQITDF-UHFFFAOYSA-N N,N-diethyl-m-toluamide Chemical compound CCN(CC)C(=O)C1=CC=CC(C)=C1 MMOXZBCLCQITDF-UHFFFAOYSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 238000006701 autoxidation reaction Methods 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 229960003949 dexpanthenol Drugs 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- 229960001673 diethyltoluamide Drugs 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000007046 ethoxylation reaction Methods 0.000 description 1
- 229940116333 ethyl lactate Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940067592 ethyl palmitate Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N hydrogen peroxide Substances OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 150000004680 hydrogen peroxides Chemical class 0.000 description 1
- 150000002443 hydroxylamines Chemical class 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- UOBSVARXACCLLH-UHFFFAOYSA-N monomethyl adipate Chemical compound COC(=O)CCCCC(O)=O UOBSVARXACCLLH-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 125000001484 phenothiazinyl group Chemical class C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- ILVGAIQLOCKNQA-UHFFFAOYSA-N propyl 2-hydroxypropanoate Chemical compound CCCOC(=O)C(C)O ILVGAIQLOCKNQA-UHFFFAOYSA-N 0.000 description 1
- FTBUKOLPOATXGV-UHFFFAOYSA-N propyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCC FTBUKOLPOATXGV-UHFFFAOYSA-N 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-L thiosulfate(2-) Chemical compound [O-]S([S-])(=O)=O DHCDFWKWKRSZHF-UHFFFAOYSA-L 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- KJIOQYGWTQBHNH-UHFFFAOYSA-N undecanol Chemical compound CCCCCCCCCCCO KJIOQYGWTQBHNH-UHFFFAOYSA-N 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10224612A DE10224612A1 (de) | 2002-06-04 | 2002-06-04 | Wirkstoffhaltige filmförmige Zubereitungen mit verbesserter chemischer Stabilität, und Verfahren zu deren Herstellung |
| DE10224612 | 2002-06-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2324909T3 true ES2324909T3 (es) | 2009-08-19 |
Family
ID=29594232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES03735367T Expired - Lifetime ES2324909T3 (es) | 2002-06-04 | 2003-05-08 | Preparado con principio activo en forma de pelicula con mejora de la estabilidad quimica y procedimiento para su fabricacion. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20050226823A1 (enExample) |
| EP (1) | EP1509201B1 (enExample) |
| JP (1) | JP2005528427A (enExample) |
| KR (1) | KR20050010024A (enExample) |
| CN (1) | CN1658833A (enExample) |
| AR (1) | AR039955A1 (enExample) |
| AT (1) | ATE426400T1 (enExample) |
| AU (1) | AU2003236632B2 (enExample) |
| BR (1) | BR0311663A (enExample) |
| CA (1) | CA2487590C (enExample) |
| DE (2) | DE10224612A1 (enExample) |
| ES (1) | ES2324909T3 (enExample) |
| RU (1) | RU2311900C2 (enExample) |
| TW (1) | TWI344373B (enExample) |
| WO (1) | WO2003101421A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2351315C2 (ru) * | 2003-07-24 | 2009-04-10 | Смитклайн Бичам Корпорейшн | Пленки, растворяющиеся в полости рта |
| DE10361306A1 (de) * | 2003-12-24 | 2005-07-28 | Lts Lohmann Therapie-Systeme Ag | Wundauflage und Wundschnellverband mit einem vasokonstriktorischen Inhaltsstoff, sowie Herstellungsverfahren hierfür |
| AR051397A1 (es) * | 2004-10-21 | 2007-01-10 | Novartis Ag | Composicion farmaceutica |
| DE102005005974A1 (de) * | 2005-02-09 | 2006-08-10 | Basf Ag | Verfahren zur Stabilisierung von Polyvinylpyrrolidonen |
| WO2006135491A2 (en) * | 2005-06-08 | 2006-12-21 | Basf Aktiengesellschaft | Medicament carrier composition and method of forming a film therefrom |
| WO2007034287A2 (en) * | 2005-09-19 | 2007-03-29 | University Of The Witwatersrand, Johannesburg | Oramucosal pharmaceutical dosage form |
| KR100742432B1 (ko) * | 2005-12-27 | 2007-07-24 | 한미약품 주식회사 | 암로디핀 캠실레이트 및 심바스타틴을 포함하는 복합제제,및 이의 제조방법 |
| FR2902655B1 (fr) * | 2006-06-23 | 2008-11-28 | Oreal | Compositon topique a effet froid |
| RU2418574C2 (ru) * | 2007-02-08 | 2011-05-20 | Медтроник Ксомед Инк. | Сольватирующая система и герметик для медицинского применения |
| JP5138765B2 (ja) * | 2008-03-18 | 2013-02-06 | 日本たばこ産業株式会社 | シガレット主流煙成分吸着剤およびシガレット用フィルタ |
| EA201170287A1 (ru) * | 2008-08-01 | 2011-10-31 | Дзе Медсинз Компани | Фармацевтические композиции и способы их стабилизации |
| ES2699077T3 (es) | 2009-06-12 | 2019-02-07 | Sunovion Pharmaceuticals Inc | Apomorfina sublingual |
| EA031156B1 (ru) | 2010-12-16 | 2018-11-30 | Суновион Фармасьютикалз Инк. | Сублингвальные пленки |
| JP5725940B2 (ja) * | 2011-04-01 | 2015-05-27 | 日東電工株式会社 | ニコチン含有貼付製剤 |
| CN103788552B (zh) * | 2012-10-26 | 2016-12-21 | 厦门加岩高分子材料有限公司 | 聚乙烯醇共混物 |
| SG11201610636VA (en) * | 2014-06-20 | 2017-01-27 | Ctc Bio Inc | Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor |
| WO2016172095A1 (en) | 2015-04-21 | 2016-10-27 | Cynapsus Therapeutics, Inc. | Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa |
| WO2017081725A1 (ja) * | 2015-11-09 | 2017-05-18 | 花王株式会社 | 口腔用組成物 |
| US11648212B2 (en) * | 2016-02-03 | 2023-05-16 | Intelgenx Corp. | Loxapine film oral dosage form |
| DE102017127452A1 (de) * | 2017-11-21 | 2019-05-23 | Lts Lohmann Therapie-Systeme Ag | Wasserlösliche Polymerklebschichten |
| WO2019171843A1 (ja) * | 2018-03-05 | 2019-09-12 | パナソニックＩｐマネジメント株式会社 | 化粧料または医療材料 |
| IT201800011125A1 (it) | 2018-12-14 | 2020-06-14 | Dpl Pharma S P A | Composizioni farmaceutiche orali solide comprendenti matrici monolitiche complesse per la somministrazione cronotropica di medicamenti nel tratto gastroenterico |
| CN110339118B (zh) * | 2019-08-19 | 2022-08-16 | 广州明辉化妆品有限公司 | 具有美白保湿功效的美白霜 |
| SE544672C2 (en) | 2020-05-07 | 2022-10-11 | Liw Innovation Ab | New compositions for oral or nasal use |
| IT202000011050A1 (it) | 2020-05-14 | 2021-11-14 | Mogon Pharmaceuticals Sagl | Composizioni orali solide comprendenti matrici monolitiche composite per la somministrazione cronotropica nel tratto gastroenterico di ingredienti attivi |
| IT202000011053A1 (it) | 2020-05-14 | 2021-11-14 | Int Health Science S R L | Composizioni orali solide comprendenti matrici monolitiche composite per la somministrazione cronotropica nel tratto gastroenterico di alimenti, integratori alimentari, nutraceutici, dispositivi medici |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2019275B3 (es) * | 1985-10-09 | 1991-06-16 | Desitin Arzneimittel Gmbh | Metodo para la produccion de una forma de administracion y de dosificacion para farmacos reactivos u otros principios activos. |
| US5032384A (en) * | 1989-01-27 | 1991-07-16 | Block Drug Company, Inc. | Compositions and method for the treatment of disease |
| IL97930A (en) * | 1991-04-23 | 1996-06-18 | Perio Prod Ltd | Preparations for whitening two controlled release products that contain a super-oxygen compound |
| JP2671248B2 (ja) * | 1991-10-23 | 1997-10-29 | ブロック・ドラッグ・カンパニー・インコーポレイテッド | 薬効または化粧効果成分の浸透性増進方法 |
| AU4327193A (en) * | 1992-07-08 | 1994-01-31 | Dianorm-Gerate G. Maierhofer | Liposomes, method of preparing them and their use in the preparation of drugs |
| DE69724424T2 (de) * | 1996-05-13 | 2004-06-24 | Novartis Consumer Health S.A. | Mundfreisetzungssystem |
| US6375963B1 (en) * | 1999-06-16 | 2002-04-23 | Michael A. Repka | Bioadhesive hot-melt extruded film for topical and mucosal adhesion applications and drug delivery and process for preparation thereof |
| RU2155071C1 (ru) * | 1999-08-10 | 2000-08-27 | Мизина Прасковья Георгиевна | Способ получения лекарственной фитопленки |
| JP5753645B2 (ja) * | 1999-11-29 | 2015-07-22 | エルテーエス ローマン テラピー−ジステーメ アーゲー | 安定性が改善された経皮治療システムおよびそれらの製法 |
| DE10018834A1 (de) * | 2000-04-15 | 2001-10-25 | Lohmann Therapie Syst Lts | Transdermale oder transmucosale Darreichungsformen mit einer nicotinhaltigen Wirkstoffkombination zur Raucherentwöhnung |
| DE10107659B4 (de) * | 2001-02-19 | 2008-03-13 | Lts Lohmann Therapie-Systeme Ag | Mucoadhäsive zerfallsfähige Arzneizubereitung zur Wirkstoffverabreichung in der Veterinär- und Humanmedizin |
| RU2195545C1 (ru) * | 2001-08-14 | 2002-12-27 | Хаминов Николай Иванович | Способ изоляции промытых зон в добывающей и нагнетательной скважинах |
-
2002
- 2002-06-04 DE DE10224612A patent/DE10224612A1/de not_active Withdrawn
-
2003
- 2003-05-08 AT AT03735367T patent/ATE426400T1/de not_active IP Right Cessation
- 2003-05-08 EP EP03735367A patent/EP1509201B1/de not_active Expired - Lifetime
- 2003-05-08 ES ES03735367T patent/ES2324909T3/es not_active Expired - Lifetime
- 2003-05-08 RU RU2004136576/15A patent/RU2311900C2/ru not_active IP Right Cessation
- 2003-05-08 CN CN03812839XA patent/CN1658833A/zh active Pending
- 2003-05-08 CA CA2487590A patent/CA2487590C/en not_active Expired - Fee Related
- 2003-05-08 DE DE50311338T patent/DE50311338D1/de not_active Expired - Lifetime
- 2003-05-08 JP JP2004508779A patent/JP2005528427A/ja active Pending
- 2003-05-08 WO PCT/EP2003/004816 patent/WO2003101421A1/de not_active Ceased
- 2003-05-08 US US10/517,087 patent/US20050226823A1/en not_active Abandoned
- 2003-05-08 AU AU2003236632A patent/AU2003236632B2/en not_active Ceased
- 2003-05-08 KR KR10-2004-7019688A patent/KR20050010024A/ko not_active Ceased
- 2003-05-08 BR BR0311663-8A patent/BR0311663A/pt not_active Application Discontinuation
- 2003-05-26 TW TW092114186A patent/TWI344373B/zh not_active IP Right Cessation
- 2003-06-04 AR ARP030101977A patent/AR039955A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW200307566A (en) | 2003-12-16 |
| ATE426400T1 (de) | 2009-04-15 |
| US20050226823A1 (en) | 2005-10-13 |
| AU2003236632B2 (en) | 2008-07-31 |
| AU2003236632A1 (en) | 2003-12-19 |
| WO2003101421A1 (de) | 2003-12-11 |
| AR039955A1 (es) | 2005-03-09 |
| TWI344373B (en) | 2011-07-01 |
| DE10224612A1 (de) | 2003-12-24 |
| BR0311663A (pt) | 2005-06-28 |
| CA2487590A1 (en) | 2003-12-11 |
| EP1509201A1 (de) | 2005-03-02 |
| EP1509201B1 (de) | 2009-03-25 |
| RU2311900C2 (ru) | 2007-12-10 |
| JP2005528427A (ja) | 2005-09-22 |
| CA2487590C (en) | 2011-01-11 |
| KR20050010024A (ko) | 2005-01-26 |
| RU2004136576A (ru) | 2005-08-27 |
| DE50311338D1 (de) | 2009-05-07 |
| CN1658833A (zh) | 2005-08-24 |
| WO2003101421A8 (de) | 2005-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2324909T3 (es) | Preparado con principio activo en forma de pelicula con mejora de la estabilidad quimica y procedimiento para su fabricacion. | |
| ES2620413T3 (es) | Formulaciones veterinarias antihelmínticas tópicas | |
| US6432415B1 (en) | Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces | |
| ES2237104T3 (es) | Dispositivo portador de productos farmaceuticos adecuado para el aporte de compuestos farmaceuticos a superficies mucosas. | |
| JPWO1999002158A1 (ja) | ４，５−エポキシモルヒナン誘導体を含有する安定な医薬品組成物 | |
| KR20000068528A (ko) | 4,5-에폭시모르피난 유도체를 함유하는 안정한 의약품 조성물 | |
| EP4076380B1 (en) | Transmucosal therapeutic system containing agomelatine | |
| Dodla et al. | Buccal penetration enhancers-an overview | |
| ATE359777T1 (de) | Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate | |
| JP2021138762A (ja) | 経口フィルム製剤 | |
| JP3207212B2 (ja) | 吸収促進剤およびこれを含有する外用剤 | |
| KR20130132496A (ko) | 아세트아미노펜의 안정화제 | |
| KR100679582B1 (ko) | 경질 쉘 캡슐용 이부프로펜 용액 | |
| EP4076381B1 (en) | Transmucosal therapeutic system containing agomelatine | |
| KR101723724B1 (ko) | 수분감응성 겔이 도포된 야누스패브릭을 포함하는 구강점막용 또는 경피흡수용 패치 | |
| WO2000024424A1 (fr) | Agents favorisant l'absorption a travers la muqueuse renfermant un acide gras insature et un gel polymere, medicaments les contenant | |
| WO2005112909A1 (ja) | 消炎鎮痛外用水性液剤 | |
| CA2303132C (en) | Intranasal formulations containing scopolamine and method of treating motion sickness | |
| JPH01203336A (ja) | 経皮・口腔粘膜適用製剤 | |
| US20050255161A1 (en) | Method for the long term stabilization of labile compounds at room temperature in pharmaceutical preparations containing water | |
| HK40110942A (en) | Transmucosal therapeutic system containing agomelatine | |
| HK40082930A (en) | Transmucosal therapeutic system containing agomelatine | |
| HK40082930B (en) | Transmucosal therapeutic system containing agomelatine | |
| JP2019006738A (ja) | 医薬組成物 | |
| HK40082929B (en) | Transmucosal therapeutic system containing agomelatine |